Crohn's Disease

Healio Gastroenterology presents the following reports on the most recent research on COVID-19 is gastrointestinal conditions.

Dietary gluten intake was not associated with risk for Crohn’s disease or ulcerative colitis, according to study results.

Researchers from Cleveland Clinic found an infection that prevents healing in patients with Crohn’s disease, according to study results published in Science.

Remicade use in inflammatory bowel disease was linked to attenuated serological response to SARs-CoV-2, which were further blunted by immunomodulators used as concomitant therapy, according to a study published in Gut.

Regardless of prior tumor necrosis factor inhibitor failure status, Xeljanz was efficacious in patients with ulcerative colitis, according to a study published in Clinical Gastroenterology and Hepatology.

The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity profiles in patients with inflammatory bowel disease, according to study results.

Childhood exposure to residential greenspace was associated with a reduced risk for inflammatory bowel disease, according to data published in the American Journal of Gastroenterology.

Patients with Crohn’s disease who undergo total hip arthroplasty may be at higher risk of medical complications, longer hospital stays and increased costs of care, according to published results.

A relatively high rate of COVID-19 vaccination intent was observed among inflammatory bowel disease populations; however, long-term safety concerns were common, according to study results.

Physicians should encourage patients with inflammatory bowel disease to get the COVID-19 vaccination despite lack of studies on the cohort, according to a presentation at the Crohn’s and Colitis Congress.